Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics (IPSC)
NASDAQ:IPSC
IPSC Stock Chart & Stats
$2.42
<$0.01(0.47%)
At close: 4:00 PM EST
$2.42
<$0.01(0.47%)
Day’s Range― - ―
52-Week Range$0.34 - $3.04
Previous CloseN/A
Volume712.78K
Average Volume (3M)1.22M
Market Cap
$434.93M
Enterprise Value$186.88M
Total Cash (Recent Filing)$117.11M
Total Debt (Recent Filing)$43.56M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
May 20, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding179,722,750
10 Day Avg. Volume1,881,603
30 Day Avg. Volume1,219,825
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.54
Price to Sales (P/S)0.79
P/FCF Ratio-0.82
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue1.71
Enterprise Value/Gross Profit1.88
Enterprise Value/Ebitda-96.38
Forecast
1Y Price Target
$5.30Price Target Upside119.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manufacturing ReadinessSecuring a master cell bank with intended immune-evasion edits and producing cryopreserved, quality-controlled beta cell products indicates manufacturing readiness for clinical supply.
Preclinical EfficacyPreclinical studies show the lead cell therapy achieved sustained blood sugar regulation and long-term cell persistence in animal models, supporting potential clinical benefit.
Regulatory PathwayConstructive interactions with the FDA suggest a clear path toward submitting an investigational new drug application for the lead program.
Bears Say
Trial Design UncertaintyUndisclosed details of the planned clinical trial design create uncertainty about how initial clinical success will be measured, increasing execution risk for early-stage programs.
Century Therapeutics News
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $0.34 and its highest was $3.04 in the past 12 months.
What is Century Therapeutics’s market cap?
Century Therapeutics’s market cap is $434.93M.
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 57 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on Mar 12, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.04.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 179,722,750 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went down -8.425%.
Which hedge fund is a major shareholder of Century Therapeutics?
Currently, no hedge funds are holding shares in IPSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Century Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.30 (119.01% Upside)
$5.30 (119.01% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $2.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 24.6%
Last 30 Days ▲ 24.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
340.00%
12-Months-Change
Fundamentals
Return on Equity
-4.88%
Trailing 12-Months
Asset Growth
-36.67%
Trailing 12-Months
Company Description
Century Therapeutics
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPSC Stock 12 Month Forecast
Average Price Target
$5.30
▲(119.01% Upside)
Technical Analysis
Tempest Therapeutics
―
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
CalciMedica
―
Ownership Overview
3.49% Insiders
1.27% Mutual Funds
5.08% Other Institutional Investors
89.00% Public Companies and
Individual Investors